About Tumor necrosis factor receptor superfamily member 14
Tumor necrosis factor receptor superfamily member 14 (TNFRSF14) is a protein
from Homo sapiens identified by UniProt accession
Q92956, 283 residues long.
MolForge cross-references it against 0 known binders and
319 disease associations.
Target properties
| Protein name | Tumor necrosis factor receptor superfamily member 14 |
|---|
| UniProt accession | Q92956 |
|---|
| Gene | TNFRSF14 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 283 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (319)
Diseases linked to this target (Open Targets).
- diffuse large B-cell lymphoma · score 0.60
- lymphoid neoplasm · score 0.46
- eosinophil count · score 0.38
- non-Hodgkins lymphoma · score 0.37
- nodal marginal zone B-cell lymphoma · score 0.37
- lymphoma · score 0.37
- prostate carcinoma · score 0.37
- skin basal cell carcinoma · score 0.37
- lung carcinoma · score 0.37
- neoplasm of mature B-cells · score 0.37
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q92956-F1 | alphafold | PREDICTED | 79.95 | — |
Amino-acid sequence (283 residues)
MEPPGDWGPP PWRSTPKTDV LRLVLYLTFL GAPCYAPALP SCKEDEYPVG SECCPKCSPG YRVKEACGEL TGTVCEPCPP GTYIAHLNGL SKCLQCQMCD PAMGLRASRN CSRTENAVCG CSPGHFCIVQ DGDHCAACRA YATSSPGQRV QKGGTESQDT LCQNCPPGTF SPNGTLEECQ HQTKCSWLVT KAGAGTSSSH WVWWFLSGSL VIVIVCSTVG LIICVKRRKP RGDVVKVIVS VQRKRQEAEG EATVIEALQA PPDVTTVAVE ETIPSFTGRS PNH
Explore Tumor necrosis factor receptor superfamily member 14 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets